Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Type
Public
HQ
Exton, US
Employees
52 (est)
Fibrocell Science is headquartered in Exton, US

Key People at Fibrocell Science

David Pernock

David Pernock

Chairman and Chief Executive Officer
Robert S. Langer

Robert S. Langer

Director
John Maslowski

John Maslowski

Vice President, Scientific Affairs
Declan Daly

Declan Daly

Chief Operating Officer and Chief Financial Officer

Fibrocell Science Locations

Exton, US

Fibrocell Science Metrics

Fibrocell Science Summary

Market capitalization

$34.9 M

Closing share price

$0.854
Fibrocell Science's latest market capitalization is $34.9 M.

Fibrocell Science Market Value History

Fibrocell Science News

Fibrocell Science Company Life

You may also be interested in